MC4R and obesity disorder: In humans, mutations in MC4R are the most common cause of genetic obesity (2, 4) and the use of setmelanotide, an MC4R agonist, is an effective pharmacotherapy for the treatment of monogenetic and syndromic obesity phenotypes (5, 6).